 |
|
Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral Arterial Disease
A Randomized Controlled Trial
Leo R. Zacharski, MD;
Bruce K. Chow, MS;
Paula S. Howes, MS, APRN;
Galina Shamayeva, MS;
John A. Baron, MD;
Ronald L. Dalman, MD;
David J. Malenka, MD;
C. Keith Ozaki, MD;
Philip W. Lavori, PhD
JAMA. 2007;297:603-610.
Context Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical–mediated oxidative stress.
Objective To test the hypothesis that reducing body iron stores through phlebotomy will influence clinical outcomes in a cohort of patients with symptomatic peripheral arterial disease (PAD).
Design, Setting, and Patients Multicenter, randomized, controlled, single-blinded clinical trial based on the Iron (Fe) and Atherosclerosis Study (FeAST) (VA Cooperative Study #410) and conducted between May 1, 1999, and April 30, 2005, within the Department of Veterans Affairs Cooperative Studies Program and enrolling 1277 patients with symptomatic but stable PAD. Those with conditions likely to cause acute-phase increase of the ferritin level or with a diagnosis of visceral malignancy within the preceding 5 years were excluded. Analysis was by intent-to-treat.
Intervention Patients were assigned to a control group (n = 641) or to a group undergoing reduction of iron stores by phlebotomy with removal of defined volumes of blood at 6-month intervals (avoiding iron deficiency) (n = 636), stratified by hospital, age, and baseline smoking status, diagnosis of diabetes mellitus, ratio of high-density to low-density lipoprotein cholesterol level, and ferritin level.
Main Outcome Measures The primary end point was all-cause mortality; the secondary end point was death plus nonfatal myocardial infarction and stroke.
Results There were no significant differences between treatment groups for the primary or secondary study end points. All-cause deaths occurred in 148 patients (23%) in the control group and in 125 (20%) in the iron-reduction group (hazard ratio (HR), 0.85; 95% confidence interval (CI), 0.67-1.08; P = .17). Death plus nonfatal myocardial infarction and stroke occurred in 205 patients (32%) in the control group and in 180 (28%) in the iron-reduction group (HR, 0.88; 95% CI, 0.72-1.07; P = .20).
Conclusion Reduction of body iron stores in patients with symptomatic PAD did not significantly decrease all-cause mortality or death plus nonfatal myocardial infarction and stroke.
Trial Registration clinicaltrials.gov Identifier: NCT00032357
Author Affiliations: White River Junction VA Medical Center, Research Service, Department of Veterans Affairs Medical Center, White River Junction, Vt (Dr Zacharski and Ms Howes); VA Palo Alto Health Care System, Research Service, Department of Veterans Affairs Medical Center, Palo Alto, Calif (Mr Chow and Ms Shamayeva and Drs Dalman and Lavori); Department of Medicine, Dartmouth Medical School, Lebanon, NH (Drs Zacharski, Baron, and Malenka); Departments of Surgery (Dr Dalman) and Health Research and Policy (Dr Lavori), Stanford University Medical School, Palo Alto; and the University of Florida College of Medicine, Gainesville, and North Florida/South Georgia Veterans Health, Research Service, Department of Veterans Affairs Medical Center, Gainesville (Dr Ozaki).
RELATED LETTERS
Iron Reduction and Cardiovascular Outcomes
Jerome L. Sullivan and Stuart D. Katz
JAMA. 2007;297(19):2075.
EXTRACT
| FULL TEXT
Iron Reduction and Cardiovascular Outcomes
Robert D. Allison, Barbara J. Bryant, Sumithira Vasu, and Susan F. Leitman
JAMA. 2007;297(19):2075-2076.
EXTRACT
| FULL TEXT
Iron Reduction and Cardiovascular Outcomes—Reply
Leo R. Zacharski and Bruce K. Chow
JAMA. 2007;297(19):2076.
EXTRACT
| FULL TEXT
RELATED ARTICLE
The Iron-Heart Hypothesis: Search for the Ironclad Evidence
Frank B. Hu
JAMA. 2007;297(6):639-641.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Serum Bilirubin and Ferritin Levels Link Heme Oxygenase-1 Gene Promoter Polymorphism and Susceptibility to Coronary Artery Disease in Diabetic Patients
Chen et al.
Diabetes Care 2008;31:1615-1620.
ABSTRACT
| FULL TEXT
Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial
Zacharski et al.
JNCI J Natl Cancer Inst 2008;100:996-1002.
ABSTRACT
| FULL TEXT
Cancer as a Ferrotoxic Disease: Are We Getting Hard Stainless Evidence?
Edgren et al.
JNCI J Natl Cancer Inst 2008;100:976-977.
FULL TEXT
Relation of iron and red meat intake to blood pressure: cross sectional epidemiological study
Tzoulaki et al.
BMJ 2008;337:a258-a258.
ABSTRACT
| FULL TEXT
Dietary iron and blood pressure
Stranges and Guallar
BMJ 2008;337:a547-a547.
FULL TEXT
Donation Frequency, Iron Loss, and Risk of Cancer Among Blood Donors
Edgren et al.
JNCI J Natl Cancer Inst 2008;100:572-579.
ABSTRACT
| FULL TEXT
Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors
Zheng et al.
Diabetes Care 2007;30:2685-2689.
ABSTRACT
| FULL TEXT
Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability
Sullivan
Exp. Biol. Med. 2007;232:1014-1020.
ABSTRACT
| FULL TEXT
The Big Idea: the coxib crisis Iron, aspirin and heart disease risk revisited
Sullivan
JRSM 2007;100:346-349.
FULL TEXT
JournalScan
Lindsay
Heart 2007;93:773-774.
FULL TEXT
Iron Reduction and Cardiovascular Outcomes
Sullivan and Katz
JAMA 2007;297:2075-2075.
FULL TEXT
Iron Reduction and Cardiovascular Outcomes
Allison et al.
JAMA 2007;297:2075-2076.
FULL TEXT
No CV Benefit of Ferritin Reduction in Older Men
Journal Watch Cardiology 2007;2007:2-2.
FULL TEXT
The Iron-Heart Hypothesis: Search for the Ironclad Evidence
Hu
JAMA 2007;297:639-641.
FULL TEXT
Does Reducing Iron Stores Improve Cardiovascular Outcomes?
JWatch General 2007;2007:7-7.
FULL TEXT
|
